TYENNE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TYENNE (TYENNE).
Tocilizumab is a recombinant humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling. This reduces pro-inflammatory cytokine production and immune activation.
| Metabolism | Tocilizumab is a monoclonal antibody; it is not metabolized by hepatic enzymes. Clearance occurs through intracellular catabolism, with linear clearance at higher doses. No CYP450 involvement. |
| Excretion | Primarily hepatic metabolism; biliary excretion of unchanged drug and metabolites is the main route of elimination, with approximately 20% of the dose recovered in feces as parent drug and metabolites. Renal excretion is minimal (<5% of the dose as unchanged drug in urine). |
| Half-life | Terminal elimination half-life is approximately 13 days (range 11–17 days) in patients with rheumatoid arthritis. This long half-life supports a monthly subcutaneous dosing interval. |
| Protein binding | Approximately 90–95% bound to plasma proteins, predominantly to albumin and to a lesser extent to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 6–8 L (about 0.09 L/kg for a 70 kg individual), indicating limited extravascular distribution and primary presence in the vascular space. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80–90% after SC injection compared to IV administration. |
| Onset of Action | Subcutaneous: Clinical effect (e.g., reduction in swollen joint count) may be observed as early as 2–4 weeks after the first dose, with maximal response typically by 12–16 weeks. |
| Duration of Action | Duration of clinical effect persists for the dosing interval (4 weeks) with monthly dosing. After discontinuation, drug concentrations decline slowly with a half-life of ~13 days, and measurable drug may persist for several months. |
800 mg intravenously over 1 hour, repeat in 4 weeks, then every 8 weeks; or 120 mg subcutaneously weekly.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A); not recommended for moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy in children have not been established. |
| Geriatric use | No specific dose adjustment; elderly patients may have higher infection risk; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TYENNE (TYENNE).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions in nursing infants (e.g., immunosuppression), advise against breastfeeding while on therapy and for at least 20 weeks after last dose (based on half-life of ~21 days). M/P ratio not available. |
| Teratogenic Risk | Pregnancy Category C. No adequate human studies. In animal studies, intravenous administration of tocilizumab (the active ingredient of TYENNE) during organogenesis resulted in embryotoxicity and increased fetal loss at doses 1.25 to 10 times the maximum recommended human dose. Based on mechanism of action (IL-6 receptor antagonist), there is a potential for disruption of normal immune development. Avoid use during pregnancy unless benefit outweighs risk. First trimester: unknown risk; second and third trimesters: theoretical risk of immune suppression in neonate. |
■ FDA Black Box Warning
Risk of serious infections leading to hospitalization or death, including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be tested for latent TB prior to therapy; if positive, treat before starting tocilizumab.
| Serious Effects |
["Known hypersensitivity to tocilizumab or any excipients","Active severe infections, including sepsis and opportunistic infections"]
| Precautions | ["Serious infections: withhold therapy if serious infection develops","Gastrointestinal perforation risk, especially in patients with diverticulitis","Hepatotoxicity: monitor liver enzymes; discontinue if significant elevation","Neutropenia and thrombocytopenia: monitor blood counts","Lipid elevations: monitor lipids 4-8 weeks after initiation","Hypersensitivity reactions including anaphylaxis","Vaccinations: avoid live vaccines during treatment","Malignancy risk: consider risk versus benefit"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of infection in mother and fetus/neonate. Perform baseline and periodic liver function tests and neutrophil counts. During pregnancy, consider ultrasound for fetal growth assessment if prolonged exposure. Monitor for maternal hypertension and hematologic abnormalities. |
| Fertility Effects | Animal studies have shown impairment of fertility (decreased implantation sites and increased post-implantation loss) at doses similar to human exposure. In humans, no formal fertility studies conducted. Theoretical risk of impaired ovulation due to IL-6 signaling modulation. |